These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28725976)

  • 1. Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):463-475. PubMed ID: 28725976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site.
    Gibiansky L; Ng CM; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2024 Dec; 51(6):703-720. PubMed ID: 38639818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target-mediated drug disposition model for drugs that bind to more than one target.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approximations of the target-mediated drug disposition model and identifiability of model parameters.
    Gibiansky L; Gibiansky E; Kakkar T; Ma P
    J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):573-91. PubMed ID: 19005743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.
    Lavezzi SM; Mezzalana E; Zamuner S; De Nicolao G; Ma P; Simeoni M
    J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):787-802. PubMed ID: 30415351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mathematical description of drug-target interactions: application to biologics that bind to targets with two binding sites.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2018 Feb; 45(1):23-34. PubMed ID: 28918570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations.
    Koch G; Jusko WJ; Schropp J
    J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):17-26. PubMed ID: 28074395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.
    Koch G; Jusko WJ; Schropp J
    J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):27-42. PubMed ID: 28074396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
    Cao Y; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):341-51. PubMed ID: 19578985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model.
    Yan X; Krzyzanski W
    J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):141-6. PubMed ID: 22215144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens.
    Yan X; Ruixo JJP; Krzyzanski W
    AAPS J; 2020 Jan; 22(2):30. PubMed ID: 31950308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validity conditions of approximations for a target-mediated drug disposition model: A novel first-order approximation and its comparison to other approximations.
    Byun JH; Jeon HS; Yun HY; Kim JK
    PLoS Comput Biol; 2024 Apr; 20(4):e1012066. PubMed ID: 38656966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
    Yan X; Mager DE; Krzyzanski W
    J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):25-47. PubMed ID: 20012173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target-mediated exposure enhancement: a previously unexplored limit of TMDD.
    Glassman PM; Muzykantov VR
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):411-420. PubMed ID: 32488574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations.
    Eudy RJ; Riggs MM; Gastonguay MR
    AAPS J; 2015 Sep; 17(5):1280-4. PubMed ID: 26077506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.
    Djebli N; Martinez JM; Lohan L; Khier S; Brunet A; Hurbin F; Fabre D
    Clin Pharmacokinet; 2017 Oct; 56(10):1155-1171. PubMed ID: 28063030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients.
    Berends SE; van Steeg TJ; Ahsman MJ; Singh S; Brandse JF; D'Haens GRAM; Mathôt RAA
    J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):543-551. PubMed ID: 31489538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of target-mediated drug disposition.
    Peletier LA; Gabrielsson J
    Eur J Pharm Sci; 2009 Dec; 38(5):445-64. PubMed ID: 19786099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.